I purchased shares in Baxter International (BAX) as the company recently reported strong Q2 earnings with raised EPS guidance, indicating robust growth and efficient operational adjustments. Despite some analyst downgrades, the strategic divestiture of Vantive and strong market positions in emerging sectors suggest significant upside potential.

I believe Baxter (BAX) is poised for growth due to its strong Q2 earnings beat and raised full-year outlook, despite recent downgrades and margin concerns. The company's strategic initiatives, including the potential sale of its kidney-care unit, add further optimism.